New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCED ABBOTT PARK, Ill. April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test. Additionally, the AACR Cancer Prevention Research Award for Outstanding Journal Article will recognize a publication on MCED multiyear outcomes from the DETECT-A study. Multi-biomarker approach enables broader and earlier cancer detection New data demonstrate how combining methylation (M) and protein (P) biomarkers improves cancer detection across stages, with each biomarker contributing independently to overall performance. Cancerguard is currently the only commercially available MCED test designed with a multi-biomarker class appr
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test [TheStreet.com]TheStreet.com
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection TestPR Newswire
- Abbott Laboratories (ABT) had its price target lowered by Royal Bank Of Canada from $135.00 to $130.00. They now have an "outperform" rating on the stock.MarketBeat
- Abbott Laboratories (ABT) had its price target lowered by Sanford C. Bernstein from $125.00 to $110.00. They now have an "outperform" rating on the stock.MarketBeat
- Abbott Laboratories (ABT) had its price target lowered by Evercore Inc from $134.00 to $120.00. They now have an "outperform" rating on the stock.MarketBeat
ABT
Earnings
- 4/16/26 - Beat
ABT
Sec Filings
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- 4/2/26 - Form 4
- ABT's page on the SEC website